^
No biomarker
Prolymphocytic Leukemia
alemtuzumab
Sensitive
:
A2
No biomarker
Prolymphocytic Leukemia
alemtuzumab
Sensitive
:
A2
NOTCH1 mutation
Prolymphocytic Leukemia
ibrutinib
Resistant
:
C3
JAK3 mutation
Prolymphocytic Leukemia
venetoclax + ruxolitinib
Sensitive
:
C3
CDKN2A deletion
Prolymphocytic Leukemia
alemtuzumab
Resistant
:
C4
STAT5B N642H
Prolymphocytic Leukemia
alemtuzumab
Resistant
:
C4
TCL1A rearrangement
Prolymphocytic Leukemia
alemtuzumab
Resistant
:
C4
RAD50 Y625
Prolymphocytic Leukemia
alemtuzumab
Resistant
:
C4
ATM D2721N
Prolymphocytic Leukemia
alemtuzumab
Resistant
:
C4
PAK4 deletion
Prolymphocytic Leukemia
alemtuzumab
Resistant
:
C4
BRAF V600E
Prolymphocytic Leukemia
alemtuzumab
Resistant
:
C4
BRAF V600E
Prolymphocytic Leukemia
venetoclax
Resistant
:
C4
BRAF V600E
Prolymphocytic Leukemia
dasatinib
Resistant
:
C4
BRAF V600E
Prolymphocytic Leukemia
vemurafenib
Sensitive
:
C4